|Title:|| Systematic evolution of ligands by exponential enrichment: tissue SELEX|
|Abstract:||This invention discloses high-affinity oligonucleotide ligands to complex tissue targets, specifically nucleic acid ligands having the ability to bind to complex tissue targets, and the methods for obtaining such ligands. Tissue targets comprise cells, subcellular components, aggregates or cells, collections of cells, and higher ordered structures. Specifically, nucleic acid ligands to red blood cells ghosts, endothelia of the blood brain and CSF-blood barriers, glioblastomas, and lymphomas are described.|
|Inventor(s):|| Heilig; Joseph S. (Boulder, CO), Gold; Larry (Boulder, CO) |
|Assignee:|| Gilead Sciences, Inc. (Foster City, CA) |
|Filing Date:||Sep 14, 1999|
|Claims:||1. A method of delivering a pharmaceutical to the brain comprising: |
conjugating the pharmaceutical to a nucleic acid ligand of a transporter molecule that is specific to or enhanced in a tissue which acts as a barrier to the brain, to form a ligand-pharmaceutical conjugate; and
administering the ligand-pharmaceutical conjugate to an animal in need of the pharmaceutical, whereby a transporter molecule-ligand-pharmaceutical conjugate complex is formed and whereby the pharmaceutical is delivered to the brain.
2. The method of claim 1 wherein said tissue is cerebral endothelium.
3. The method of claim 1 wherein said tissue is choroid plexus epithelium.